Should I buy or sell MaxCyte stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MaxCyte in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MXCT shares. View MXCT analyst ratings or view top-rated stocks .

What is MaxCyte's stock price target for 2024?

4 brokers have issued 1-year price targets for MaxCyte's shares. Their MXCT share price targets range from $7.00 to $11.00. On average, they predict the company's stock price to reach $8.67 in the next year. This suggests a possible upside of 122.2% from the stock's current price. View analysts price targets for MXCT or view top-rated stocks among Wall Street analysts .

How have MXCT shares performed in 2024?

MaxCyte's stock was trading at $4.70 at the beginning of the year. Since then, MXCT stock has decreased by 17.0% and is now trading at $3.90. View the best growth stocks for 2024 here .

When is MaxCyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our MXCT earnings forecast .

How can I listen to MaxCyte's earnings call?

MaxCyte will be holding an earnings conference call on Tuesday, May 7th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link .

How were MaxCyte's earnings last quarter?

MaxCyte, Inc. (NASDAQ:MXCT) announced its earnings results on Tuesday, March, 12th. The company reported ($0.05) EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.05. The business earned $15.67 million during the quarter, compared to the consensus estimate of $15.60 million. MaxCyte had a negative trailing twelve-month return on equity of 15.90% and a negative net margin of 91.85%.

What guidance has MaxCyte issued on next quarter's earnings?

MaxCyte updated its FY 2024 earnings guidance on Monday, March, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $29.6 million-$31.3 million, compared to the consensus revenue estimate of $42.1 million.

When did MaxCyte IPO?

MaxCyte (MXCT) raised $150 million in an IPO on Friday, July 30th 2021. The company issued 12,000,000 shares at $11.50-$13.50 per share.

Who are MaxCyte's major shareholders?

MaxCyte's stock is owned by a number of retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.27%) and Salem Investment Counselors Inc. (0.05%). Insiders that own company stock include Casdin Partners Master Fund, L, Douglas Doerfler, John Joseph Johnston, Richard Douglas and Thomas M Ross. View institutional ownership trends .

How do I buy shares of MaxCyte?

Shares of MXCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:MXCT

MaxCyte (MXCT) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free MXCT Stock Alerts

$3.95

+0.07 (+1.80%)

(As of 04:00 PM ET)

Compare

Today's Range: $3.81
▼
$3.97
50-Day Range: $3.88
▼
$4.95
52-Week Range: $2.45
▼
$5.55

Volume: 534,108 shs
Average Volume: 634,303 shs
Market Capitalization: $412.38 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.67

Get MaxCyte alerts:

MaxCyte MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 122.2% Upside
$8.67 Price Target
Short Interest: Bearish
3.57% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$47,650 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.53) to ($0.46) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.00 out of 5 stars

Medical Sector

575th out of 918 stocks

Commercial Physical Research Industry

10th out of 11 stocks

3.5

Analyst's Opinion

Consensus Rating
MaxCyte has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
MaxCyte has only been the subject of 3 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
3.57% of the float of MaxCyte has been sold short.
Short Interest Ratio / Days to Cover
MaxCyte has a short interest ratio ("days to cover") of 5.1.
Change versus previous month
Short interest in MaxCyte has recently increased by 4.49%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
MaxCyte does not currently pay a dividend.
Dividend Growth
MaxCyte does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MXCT.

N/A

News and Social Media Coverage

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, MaxCyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $47,650.00 in company stock.
Percentage Held by Insiders
Only 6.00% of the stock of MaxCyte is held by insiders.
Percentage Held by Institutions
68.81% of the stock of MaxCyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for MaxCyte are expected to grow in the coming year, from ($0.53) to ($0.46) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of MaxCyte is -10.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of MaxCyte is -10.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
MaxCyte has a P/B Ratio of 1.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About MaxCyte Stock (NASDAQ:MXCT)

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

MXCT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MXCT Stock News Headlines

March 29, 2024 | insidertrades.com

Insider Selling: MaxCyte, Inc. (NASDAQ:MXCT) Director Sells 5,000 Shares of Stock

April 10, 2024 | globenewswire.com

MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

April 5, 2024 | msn.com

Mesa Laboratories maintains quarterly dividend of $0.16

April 2, 2024 | globenewswire.com

MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)

March 17, 2024 | finance.yahoo.com

Downgrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near Term

March 15, 2024 | finanznachrichten.de

MaxCyte, Inc: MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance

March 14, 2024 | finance.yahoo.com

MaxCyte, Inc. (LON:MXCT) Just Reported And Analysts Have Been Cutting Their Estimates

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

March 13, 2024 | marketwatch.com

MaxCyte Shares Rise 13% After 4Q Beat, Reaffirmed Guidance

March 12, 2024 | globenewswire.com

MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance

March 12, 2024 | globenewswire.com

MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance

March 6, 2024 | finanznachrichten.de

MaxCyte, Inc.: MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results

March 4, 2024 | globenewswire.com

MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results

March 4, 2024 | globenewswire.com

MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results

February 9, 2024 | finance.yahoo.com

MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences

January 30, 2024 | finance.yahoo.com

MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers

January 23, 2024 | markets.businessinsider.com

MaxCyte Signs SPL Agreement With Imugene

January 9, 2024 | msn.com

Why Cell Engineering Company MaxCyte Shares Are Up Today

January 9, 2024 | seekingalpha.com

COMM, NKTX and AVIR are among after hour movers

January 5, 2024 | benzinga.com

MaxCyte Stock (NASDAQ:MXCT) Dividends: History, Yield and Dates

January 3, 2024 | finance.yahoo.com

MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline

January 2, 2024 | finanznachrichten.de

MaxCyte, Inc: MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director

January 2, 2024 | msn.com

MaxCyte gets new CEO and President

January 2, 2024 | finance.yahoo.com

MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director

December 15, 2023 | finance.yahoo.com

With 74% institutional ownership, MaxCyte, Inc. (LON:MXCT) is a favorite amongst the big guns

December 11, 2023 | marketwatch.com

MaxCyte Names Maher Masoud CEO

See More Headlines

Receive MXCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/12/2024
Today: 4/19/2024
Next Earnings (Confirmed): 5/07/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Commercial physical research
Sub-Industry: N/A
Current Symbol: NASDAQ:MXCT
CUSIP: N/A
CIK: 1287098
Web: maxcyte.com
Phone: 301-944-1700
Fax: 301-944-1703
Employees: 143
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $8.67
High Stock Price Target: $11.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +123.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.37)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-37,920,000.00
Net Margins: -91.85%
Pretax Margin: -91.85%
Return on Equity: -15.90%
Return on Assets: -13.94%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.65
Quick Ratio: 9.97

Sales & Book Value

Annual Sales: $41.29 million
Price / Sales: 9.81
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.23 per share
Price / Book: 1.74

Miscellaneous

Outstanding Shares: 104,396,000
Free Float: 98,132,000
Market Cap: $405.06 million
Optionable: Optionable
Beta: 1.34

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Maher Masoud (Age 48)
President, CEO, Secretary & Director
Comp: $612.07k
Mr. Douglas Arthur Doerfler (Age 68)
Founder
Comp: $1.2M
Mr. Douglas J. Swirsky CFA (Age 55)
CPA, Chief Financial Officer
Mr. Jay Gelfman
Senior Vice President of Operations
Mr. Ronald Evan Holtz CPA (Age 66)
Ph.D., Executive Vice President of Administration
Comp: $649.38k
Mr. Sean Menarguez
Director of Investor Relations
Mr. David Sandoval
Senior Vice President & General Counsel
Mr. Thomas Michael Ross (Age 63)
Executive Vice President of Global Sales
Mr. Jack Horgan
Vice President of Corporate Development
Ms. Jill Mayer
Senior Vice President of Human Resources

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MXCT Stock Analysis - Frequently Asked Questions

Should I buy or sell MaxCyte stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MaxCyte in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MXCT shares.
View MXCT analyst ratings or view top-rated stocks.
What is MaxCyte's stock price target for 2024?: 4 brokers have issued 1-year price targets for MaxCyte's shares. Their MXCT share price targets range from $7.00 to $11.00. On average, they predict the company's stock price to reach $8.67 in the next year. This suggests a possible upside of 122.2% from the stock's current price.
View analysts price targets for MXCT or view top-rated stocks among Wall Street analysts.
How have MXCT shares performed in 2024?: MaxCyte's stock was trading at $4.70 at the beginning of the year. Since then, MXCT stock has decreased by 17.0% and is now trading at $3.90.
View the best growth stocks for 2024 here.
When is MaxCyte's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our MXCT earnings forecast.
How can I listen to MaxCyte's earnings call?: MaxCyte will be holding an earnings conference call on Tuesday, May 7th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.
How were MaxCyte's earnings last quarter?: MaxCyte, Inc. (NASDAQ:MXCT) announced its earnings results on Tuesday, March, 12th. The company reported ($0.05) EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.05. The business earned $15.67 million during the quarter, compared to the consensus estimate of $15.60 million. MaxCyte had a negative trailing twelve-month return on equity of 15.90% and a negative net margin of 91.85%.

What guidance has MaxCyte issued on next quarter's earnings?: MaxCyte updated its FY 2024 earnings guidance on Monday, March, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $29.6 million-$31.3 million, compared to the consensus revenue estimate of $42.1 million.
When did MaxCyte IPO?: MaxCyte (MXCT) raised $150 million in an IPO on Friday, July 30th 2021. The company issued 12,000,000 shares at $11.50-$13.50 per share.
Who are MaxCyte's major shareholders?: MaxCyte's stock is owned by a number of retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.27%) and Salem Investment Counselors Inc. (0.05%). Insiders that own company stock include Casdin Partners Master Fund, L, Douglas Doerfler, John Joseph Johnston, Richard Douglas and Thomas M Ross.
View institutional ownership trends.
How do I buy shares of MaxCyte?: Shares of MXCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MXCT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

MaxCyte (MXCT) Stock Price, News & Analysis

MaxCyte MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

Company Ownership

Earnings and Valuation

About MaxCyte Stock (NASDAQ:MXCT)

MXCT Stock Price History

MXCT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

MXCT Stock Analysis - Frequently Asked Questions

Overall MarketRank^™